Moleculin Biotech Financials
| MBRX Stock | USD 2.69 0.07 2.67% |
| Current Value | Last Year | Change From Last Year | 10 Year Trend | ||||||
|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 4.69 | 3.8552 |
|
|
The financial analysis of Moleculin Biotech is a critical element in measuring its lifeblood. Investors should not minimize Moleculin Biotech's ability to pay suppliers or employees on time, ensuring interest payments are not accumulating.
Net Income |
|
Moleculin | Select Account or Indicator |
Understanding current and past Moleculin Biotech Financials, including the trends in assets, liabilities, equity and income are directly related to making proper and timely investing decisions. All of Moleculin Biotech's financial statements are interrelated, with each one affecting the others. For example, an increase in Moleculin Biotech's assets may result in an increase in income on the income statement.
Please note, the imprecision that can be found in Moleculin Biotech's accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of Moleculin Biotech. Check Moleculin Biotech's Beneish M Score to see the likelihood of Moleculin Biotech's management manipulating its earnings.
Moleculin Biotech Stock Summary
Moleculin Biotech competes with Bright Minds, HP, Intel, Chevron Corp, and Coca Cola. Moleculin Biotech, Inc., a clinical-stage pharmaceutical company, focuses on the development of drug candidates for the treatment of highly resistant tumors and viruses. Moleculin Biotech, Inc. was incorporated in 2015 and is headquartered in Houston, Texas. Moleculin Biotech operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 13 people.Specialization | Health Care, Pharmaceuticals, Biotechnology & Life Sciences |
| Instrument | USA Stock View All |
| Exchange | NASDAQ Exchange |
| ISIN | US60855D2009 |
| CUSIP | 60855D101 60855D200 60855D309 |
| Location | Texas; U.S.A |
| Business Address | 5300 Memorial Drive, |
| Sector | Biotechnology |
| Industry | Health Care |
| Benchmark | Dow Jones Industrial |
| Website | moleculin.com |
| Phone | (713) 300 5160 |
| Currency | USD - US Dollar |
Moleculin Biotech Key Financial Ratios
| Return On Equity | -1.41 | ||||
| EBITDA | (29.5 M) | ||||
| Net Income | (29.77 M) | ||||
| Cash Per Share | 2.03 X | ||||
| Debt To Equity | 0.01 % |
Moleculin Biotech Key Balance Sheet Accounts
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Total Assets | 25.2M | 29.0M | 84.1M | 57.4M | 38.2M | 35.4M | |
| Other Current Liab | 164K | 1.7M | 2.2M | 2.6M | 4.2M | 4.4M | |
| Net Tangible Assets | 3.1M | 4.4M | 6.6M | 67.8M | 78.0M | 81.9M | |
| Net Debt | (10.4M) | (14.9M) | (70.7M) | (42.7M) | (23.0M) | (24.1M) | |
| Retained Earnings | (39.6M) | (56.9M) | (72.8M) | (101.8M) | (131.6M) | (125.0M) | |
| Accounts Payable | 2.2M | 1.1M | 1.4M | 2.1M | 2.5M | 1.5M | |
| Cash | 10.7M | 15.2M | 70.9M | 43.1M | 23.6M | 22.4M | |
| Total Liab | 9.7M | 11.3M | 5.1M | 5.2M | 12.1M | 6.5M | |
| Total Current Assets | 13.5M | 17.2M | 72.5M | 45.6M | 26.3M | 24.0M | |
| Short Term Debt | 103K | 118K | 96K | 116K | 100K | 174.4K | |
| Common Stock | 21K | 29K | 46K | 69K | 33K | 33.6K | |
| Other Liab | 1.4M | 5.8M | 8.2M | 1.4M | 1.6M | 3.1M | |
| Capital Surpluse | 31.6M | 40.6M | 55.1M | 74.7M | 85.9M | 48.7M | |
| Other Current Assets | 529K | 2.0M | 1.1M | 1.6M | 3.2M | 3.3M | |
| Net Invested Capital | 15.6M | 17.8M | 79.0M | 52.2M | 26.1M | 34.9M | |
| Net Working Capital | 9.9M | 14.3M | 68.9M | 40.8M | 19.5M | 25.7M | |
| Net Receivables | 11K | 1K | 45K | 22K | 99K | 104.0K |
Moleculin Biotech Key Income Statement Accounts
An income statement is very similar to a cash flow statement, but instead of showing net revenue minus expenses, it only includes earnings before interest and taxes (EBIT). This number does not have all of the same line items that are on a cash flow statement, but it leaves out non-cash expenses like depreciation and amortization. For example, if you bought $100 worth of goods from Walmart (WMT) using your debit card that has an interest rate of 20%, then paid off the balance at the end of the month with a credit card that charges 30% interest, you would have an income statement showing EBIT of $80 because your expenses are lower than the amount that went into your pocket.
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Interest Income | 4.1M | 13K | 306K | 240K | 1.2M | 965.1K | |
| Interest Expense | 8.2M | 13K | 7.1M | 1.6M | 1.9M | 2.3M | |
| Gross Profit | (185K) | (285K) | (260K) | (222K) | (127K) | (133.4K) | |
| Operating Income | (17.5M) | (19.7M) | (23.0M) | (30.6M) | (29.6M) | (28.1M) | |
| Ebit | (21.6M) | (19.8M) | (23.1M) | (30.7M) | (29.6M) | (28.1M) | |
| Research Development | 11.0M | 12.8M | 14.4M | 19.0M | 19.5M | 11.3M | |
| Ebitda | (21.4M) | (19.5M) | (22.8M) | (30.5M) | (29.5M) | (28.0M) | |
| Cost Of Revenue | 185K | 285K | 260K | 222K | 127K | 143.1K | |
| Income Before Tax | (13.4M) | (17.4M) | (15.9M) | (29.0M) | (29.8M) | (28.3M) | |
| Net Income | (13.2M) | (15.0M) | (8.9M) | (27.4M) | (29.8M) | (28.3M) | |
| Income Tax Expense | (229K) | (2.4M) | (7.0M) | (1.6M) | (1.5M) | (1.5M) |
Moleculin Biotech Key Cash Accounts
Cash flow analysis captures how much money flows into and out of Moleculin Biotech. It measures of how well Moleculin is doing because it can show the actual money that comes into and out of the Company from sales instead of measuring expenses against revenue to determine earnings. You have to read the cash flow statement in three sections. The first section shows how much money Moleculin Biotech brought in, usually known as net revenue or sales. This is different from earnings because it does not include expenses when determining net revenue for use on this part of the cash flow statement. Next, are operating activities, which show how much money Moleculin had leftover after paying for its expenses. This number can be calculated in two ways: by subtracting the total of all operating expenses from net revenue or by adding up changes to cash and other assets or liabilities on this part of the statement. The third section is about investing activities, which shows what Moleculin Biotech has done with the money that it received from the sale of assets or what it spent to acquire new ones. This section can be broken down into two parts: investing in existing businesses (in other words, buying more stock) and investing in non-business activities like paying off debt or making acquisitions.
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Change In Cash | 3.6M | 4.4M | 55.7M | (27.8M) | (19.6M) | (18.6M) | |
| Free Cash Flow | (17.3M) | (18.1M) | (19.0M) | (27.7M) | (24.2M) | (23.0M) | |
| Depreciation | 199K | 200K | 164K | 130K | 127K | 112.9K | |
| Other Non Cash Items | 476K | 85K | 96K | (1.2M) | 1.9M | 2.0M | |
| Capital Expenditures | 52K | 376K | 19K | 67K | 124K | 137.6K | |
| Net Income | (13.2M) | (17.4M) | (15.9M) | (29.0M) | (29.8M) | (28.3M) | |
| End Period Cash Flow | 10.7M | 15.2M | 70.9M | 43.1M | 23.6M | 22.4M | |
| Change To Netincome | (2.0M) | (2.5M) | (575K) | (4.3M) | (3.8M) | (3.6M) | |
| Investments | (51K) | (374K) | (19K) | (67K) | (43K) | (45.2K) |
Moleculin Financial Ratios Relationships
Comparative valuation techniques use various fundamental indicators to help in determining Moleculin Biotech's current stock value. Our valuation model uses many indicators to compare Moleculin Biotech value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Moleculin Biotech competition to find correlations between indicators driving Moleculin Biotech's intrinsic value. More Info.Moleculin Biotech is considered to be number one stock in return on equity category among its peers. It is regarded third in return on asset category among its peers . At this time, Moleculin Biotech's Return On Equity is fairly stable compared to the past year. The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Moleculin Biotech's earnings, one of the primary drivers of an investment's value.Moleculin Biotech Systematic Risk
Moleculin Biotech's systematic risk plays a vital role in portfolio allocation when considering its stock to be added to a well-diversified portfolio. Moleculin Biotech volatility which cannot be eliminated through diversification, requires returns over the risk-free rate. Over the long run, a well-diversified portfolio provides returns that match its exposure to systematic risk. In this case, investors face a trade-off between expected returns and systematic risk and, therefore, can only reduce a portfolio's exposure to systematic risk by sacrificing expected returns on the portfolio.
The output start index for this execution was fourteen with a total number of output elements of fourty-seven. The Beta measures systematic risk based on how returns on Moleculin Biotech correlated with the market. If Beta is less than 0 Moleculin Biotech generally moves in the opposite direction as compared to the market. If Moleculin Biotech Beta is about zero movement of price series is uncorrelated with the movement of the benchmark. if Beta is between zero and one Moleculin Biotech is generally moves in the same direction as, but less than the movement of the market. For Beta = 1 movement of Moleculin Biotech is generally in the same direction as the market. If Beta > 1 Moleculin Biotech moves generally in the same direction as, but more than the movement of the benchmark.
Today, most investors in Moleculin Biotech Stock are looking for potential investment opportunities by analyzing not only static indicators but also various Moleculin Biotech's growth ratios. Consistent increases or decreases in fundamental ratios usually indicate a possible pattern that can be successfully translated into profits. However, when comparing two companies, knowing each company's growth growth rates may not be enough to decide which company is a better investment. That's why investors frequently use static breakdown of Moleculin Biotech growth as a starting point in their analysis.
Price Earnings To Growth Ratio |
|
Moleculin Biotech November 28, 2024 Opportunity Range
Along with financial statement analysis, the daily predictive indicators of Moleculin Biotech help investors to analyze its daily demand and supply, volume, patterns, and price swings to determine the real value of Moleculin Biotech. We use our internally-developed statistical techniques to arrive at the intrinsic value of Moleculin Biotech based on widely used predictive technical indicators. In general, we focus on analyzing Moleculin Stock price patterns and their correlations with different microeconomic environment and drivers. We also apply predictive analytics to build Moleculin Biotech's daily price indicators and compare them against related drivers.
| Downside Deviation | 4.6 | |||
| Information Ratio | 0.0099 | |||
| Maximum Drawdown | 35.41 | |||
| Value At Risk | (7.01) | |||
| Potential Upside | 9.75 |
Additional Tools for Moleculin Stock Analysis
When running Moleculin Biotech's price analysis, check to measure Moleculin Biotech's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Moleculin Biotech is operating at the current time. Most of Moleculin Biotech's value examination focuses on studying past and present price action to predict the probability of Moleculin Biotech's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Moleculin Biotech's price. Additionally, you may evaluate how the addition of Moleculin Biotech to your portfolios can decrease your overall portfolio volatility.